CGRP1 Antibody (4) - BSA Free

Immunohistochemistry-Paraffin: CGRP Antibody (4) - BSA Free [NBP3-00519] - Paraffin embedded rat tissue stained with CGRP Antibody (4) - BSA Free diluted 1:400 in 1% BSA/PBS and incubated overnight.

• Reactivity: Hu, Rt
• Applications: ELISA, IHC
• Clone: 4
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

CGRP1 Antibody (4) - BSA Free Summary

• Description: CULTURE MEDIUM: RPMI 1640 with 10% fetal calf serum FUSION PARTNER: SP2mIL6 IMMUNIZATION: Female NMRI x BALB/c mice immunized by intraperitoneal injection
• Immunogen: Synthetic human alpha-CGRP
• Epitope: The epitope lies within residues 19-37 of human alpha-CGRP.
• Specificity: This antibody binds human alpha-CGRP. Based on inhibition ELISA, this antibody cross-reacts up to 12% with human beta-CGRP and human amylin, while there is little (<4%) cross-reaction with rat alpha-CGRP.
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: CALCA
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin
• Application Notes: ELISA: NBP3-00519 binds free human a-CGRP in solution. NBP3-00519 (as biotinylated detection antibody) forms a sandwich ELISA pair with NBP3-00518 (as capture antibody) for measuring human a-CGRP, giving a detection limit of 0.13 nmol/L in an unoptimized buffer assay.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 10mM Phosphate (pH 7.4) and 0.5M NaCl
• Preservative: 0.09% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Protein A or G purified

Alternate Names for CGRP1 Antibody (4) - BSA Free

• a-CGRP
• alpha-CGRP
• alpha-type CGRP
• CALCA
• calcitonin gene-related peptide I
• calcitonin/calcitonin-related polypeptide, alpha
• calcitonin; calcitonin gene-related peptide 1
• CGRP 1
• CGRP alpha
• CGRP I
• CGRP1
• CGRP-I

Background

Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide that functions as a vasodilator, has an important role in pain pathways, and has become a target for migraine treatment (1). The CGRP peptide is characterized by an N-terminal disulfide bond, an alpha-helical structure than plays a role in binding affinity, and an amine C-terminal (1,2). CGRP exists in alpha- and beta-isoforms encoded by genes CALCA (CALC I) and CALCB (CALC II), respectively (1,2). alphaCGRP and betaCGRP only differ by three amino acids, have greater than 90% homology, and each peptide has a theoretical molecular weight of ~3.8 kDa (1,2). alphaCGRP is the predominant peptide form and is expressed in regions of the central and peripheral nervous system, including sensory fibers and the trigeminal ganglia (1,2). Other members of the CGRP gene family includes adrenomedullin, and adrenomedullin 2 (intermedin), amylin, and calcitonin (1,2). When CGRP is released from nerve fibers and blood vessels, it binds a CGRP receptor complex (1-3). The receptor consists of G-protein coupled receptor calcitonin-like receptor (CLR) that is associated with an accessory protein receptor activity-modifying protein (RAMP) (2,3).

Signaling of CGRP and its receptor are involved in vasodilation, neurogenic inflammation, and peripheral sensitization of nociceptors, all of which relate to migraine pathophysiology (2-3). Studies have found that CGRP is both released during migraines and can also induce migraines (3-5). Under normal conditions CGRP levels are typical and neurotransmission is relative; however, migraine triggers including light and sound can increase CGRP levels, enhance neurotransmission, and alter the pain and sensory aversions associated with migraines (2). Given its role, CGRP and its receptor have been the target of many migraine therapeutics including small molecule agonists called gepants and monoclonal antibodies (3-5). Ubrogepant and Rimegepant, two small molecule CGRP receptor agonists, have been FDA approved while another agonist, Atogepant, is ongoing in clinical trials (3,5). Additionally, four monoclonal antibodies against either CGRP or its receptor that are used to block signaling have been FDA approved: Eptinezumab, Fremanezumab, Galcanezumab, and Erenumab (3-5).

References

1. Russell, F. A., King, R., Smillie, S. J., Kodji, X., & Brain, S. D. (2014). Calcitonin gene-related peptide: physiology and pathophysiology. Physiological reviews, 94(4), 1099-1142. https://doi.org/10.1152/physrev.00034.2013

2. Russo A. F. (2015). Calcitonin gene-related peptide (CGRP): a new target for migraine. Annual review of pharmacology and toxicology, 55, 533-552. https://doi.org/10.1146/annurev-pharmtox-010814-124701

3. Wattiez, A. S., Sowers, L. P., & Russo, A. F. (2020). Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert opinion on therapeutic targets, 24(2), 91-100. https://doi.org/10.1080/14728222.2020.1724285

4. Deen, M., Correnti, E., Kamm, K., Kelderman, T., Papetti, L., Rubio-Beltran, E., Vigneri, S., Edvinsson, L., Maassen Van Den Brink, A., & European Headache Federation School of Advanced Studies (EHF-SAS) (2017). Blocking CGRP in migraine patients - a review of pros and cons. The journal of headache and pain, 18(1), 96. https://doi.org/10.1186/s10194-017-0807-1

5. de Vries, T., Villal0n, C. M., & MaassenVanDenBrink, A. (2020). Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacology & therapeutics, 211, 107528. https://doi.org/10.1016/j.pharmthera.2020.107528

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: CALCA